Molecular targeted therapy using specific inhibitors for activated oncogene products has started and replaced conventional chemotherapy in LADC due to high efficacy 9, 10) . To further expand the personalized therapy, it is important to find druggable targets as well as to develop diagnostic methods that are able to identify gene mutations and rearrangements. After identification of such targetable genes, patients can be treated by existing targeted therapies or by participating in appropriate clinical trials. For further facilitating personalized therapy, clinical sequencing of cancer genome in each lung cancer patient will help decision-making for treatment selection.
In this review, we discuss the current topics of targeted therapies in lung cancer based on driver gene aberrations and clinical sequencing to expand those therapies. In addition, we also discuss the current topic of immunotherapy, which is expected to be a next personalized therapy in lung cancer. Immune checkpoint blockade of the programmed death-1 (PD-1) and its ligand PD-L1 pathway showed marked effectiveness in patients with lung cancer [11] [12] [13] . While the efficacy of anti-PD-1 treatment is varies among patients, a predictive biomarker has not yet been determined. Although candidate responders for PD-1/PD-L1 blockade therapy seem to be patients with higher PD-L1 expression by immunohistochemistry (IHC) or a higher number of nonsynonymous mutations, further discussion is needed 11, 14) .
Identification, diagnosis and targeted therapy of driver genes in lung cancer
During the development of cancer, a number of genetic alterations occur. Among a huge number of mutated genes, several oncogene activations have a pivotal role in the development of cancer, and such genes are called driver genes. The driver gene aberrations induce the constitutive activation of intracellular signaling, making cancer cells oncogene-addicted (i.e., living strongly dependent on the oncogene activations) 15) . In fact, molecular targeted therapy that inhibits driver gene-induced signaling demonstrates higher specificity and higher cytotoxic rate than conventional cytotoxic anticancer agents.
To date, several (candidate) driver genes have been identified in lung cancer by whole genome sequencing, RNA sequencing, or whole exon sequencing ( Table 1 ). The effectiveness of targeted therapy against driver genes is dependent on the accurate diagnosis of these genomic aberrations in each tumor. For the diagnosis of driver gene mutations, DNA extracted from surgical specimens is subjected to PCR-based assays. On the other hand, gene fusions are detected by using fluorescence in situ hybridization (FISH) and/or IHC. The effort to diagnose multiple driver gene aberrations by a single assay, using next-generation sequencers using a small amount of genomic DNA obtained from biopsied tumor tissues, is currently underway.
LADC
LADC, which is the most common histologic subtype of NSCLC, can be classified into several subtypes according to driver gene aberrations ( Fig. 1 ). This classification is directly associated with therapeutic response to specific molecular targeted drugs. Patients harboring activating mutations of EGFR are treated using several TKIs, and show dramatic response rate and longer survival. Patients harboring ALK fusions are now standardly treated using TKIs, crizotinib and alectinib, and also have yielded a good therapeutic outcome. Based on these significant successful therapy as with EGFR mutations and ALK fusions, clinical trials have been started for other driver genes, such as RET and ROS1 fusions and HER2 and BRAF mutations 10, 16) .
Oncogenic RET fusions were identified in a small subset of LADC (1-2%) by us and others [17] [18] [19] . The RET gene was fused to the KIF5B or CCDC6 genes, resulting in the activation of tumor cell proliferation. RET fusion transgenic mice developed a high incidence of lung adenocarcinoma, confirming the lung carcinogenic activity of KIF5B-RET fusion 20) . Patients of fusion-positive cases, including ALK, ROS1 and RET fusions, often include young female and/or never/light-smokers 21, 22) . In addi- tion, fusion-positive cases show a distinct profile with smaller numbers of nonsynonymous mutations in cancerrelated genes than in other LADC cases 3) . This result reenforced that oncogenic fusion products are a primary target of cancer therapy. Pan-negative patients, whose tumors are negative for known driver gene aberrations, account for approxi-mately 30% of all LADC cases. Among such cases, several new driver genes have been identified, such as NTRK1 fusions 23) and NRG1 fusions 24, 25) . NRG1 fusions were preferentially detected in invasive mucinous lung adenocarcinoma. In addition, amplification and aberrant splicing of MET, RIT1 mutations, and MEK1 (MAP2K1) mutations were also mutually exclusively detected and ALK fusion： Crizotinib, Alectinib, Ceritinib EGFR mutation: Gefitinib, Erlotinib, Afatinib Fig. 1 The proportion of driver genes in Japanese lung adenocarcinoma (LADC) and approved (in blue) or candidate (in black) targeted drugs against driver gene aberrations. Driver mutations in EGFR, KRAS, HER2, and BRAF, and driver fusions involving ALK, RET, and ROS1 were examined in 608 LADC patients who had undergone surgical resection at the National Cancer Center. This figure was modified from our previous report 3) .
RET fusion： Vandetanib, Cabozantinib

HER2 mutation：Lapatinib
BRAF mutation：Vemurafenib, Dabrafenib
ROS1 fusion：Crizotinib
are considered to be new driver genes 1, 26) . In addition, inactivating mutations in chromatin remodeling genes, such as SMARCA4/BRG1 and ARID1A, are a promising target for synthetic lethal therapy, since several synthetic lethal targets for those mutations have been reported by us and others 27, 28) .
SQLC
SQLC is still a disease for which targeted therapy has not progressed due to the low frequency of activating mutation in oncogenes encoding tyrosine kinases. Because the FGFR (fibroblast growth factor receptor) genes are genetically activated in several cancers, their specific TKIs have been developed to treat the cases with those alterations 2) . Amplifications of FGFR1 and activating mutations of FGFR2 and FGFR3 have been identified in SQLC. Furthermore, FGFR3-TACC3 fusion was also identified in a small subset of SQLC cases and is expected to be a therapeutic target 29) . Even though these mutations, which drive SQLC development, are not frequently detected, they have a potential to be a new therapeutic target. In fact, several clinical trials have been conducted to examine the efficacy of TKIs for SQLC with FGFR amplifications or mutations 30) .
Immunotherapy is one of the major breakthroughs of cancer therapy 31, 32) . Inhibition of interactions between PD-1 and PD-1 ligands, PD-L1 and PD-L2, overcomes immune resistance and has shown durable clinical responses in various cancers, including NSCLC 11, 12, 33) . Anti-PD-1 drugs were approved for the treatmentrefractory unresectable melanoma; nivolumab in the US and Japan or pembrolizumab in the US. Nivolumab and pembrolizumab were also approved for chemotherapyrefractory SQLC in the US 34, 35) (Table 2 ). PD-1 blockade therapy has not become a personalized therapy yet due to a lack of biomarkers of responses to anti-PD-1 drugs. However, after the establishment of specific predictors, immunotherapy will be a personalized therapy for SQLC, which has few druggable targets.
SCLC
Although SCLC is the deadliest type of lung cancer with poor prognosis, the standard therapy for SCLC has not changed and molecular targeted therapy has not yet been applied in the clinical setting 36) . According to recent results of large scale genomic analyses, inactivation of TP53 and RB1 was recurrently identified and, therefore, those genes were considered to drive SCLC development 37, 38) . Amplification of MYC and mutations in CREBBP/CBP and EP300 that are histone acetylation enzyme and in PTEN were also identified in SCLC 39) . Furthermore, the oncogenic PI3K/AKT/mTOR pathway was activated, which could be a potential therapeutic target in SCLC 40) . However, activating mutation in kinase genes have rarely been identified in SCLC, and no kinase inhibitors have been used in personalized therapy for SCLC.
Blockade of the PD-1/PD-L1 pathway is also another potential therapeutic target in SCLC. A small subset of SCLC cases demonstrated that CD274/PD-L1, which is located on chromosome 9p24.1, showed arm-level or focal amplifications 41) . Although it is still unknown whether PD-L1 expression is associated with the response of anti-PD-1 treatment, immune checkpoint blockade therapy is also expected to be a promising targeted therapy for SCLC.
Clinical genome sequencing for the entry to clinical trials
A large-scale trial has been started with the aim of finding patients harboring rare driver genes and trying to adapt molecular targeted therapy accordingly. LC-SCRUM-Japan (Lung Cancer Genomic Screening Project for Individualized Medicine in Japan) is one of the successful consortiums that has screened driver genes in advanced NSCLC without EGFR mutations, in over 190 Japanese institutions (http://epoc.ncc.go.jp/ scrum/lc_scrum/). After the diagnosis of driver genes, patients with NSCLC harboring RET fusions, ROS1 fusions, ALK fusions or BRAF mutations participated in appropriate clinical trials. A phase II clinical trial, which was designed to evaluate the therapeutic response of vandetanib for advanced RET fusions patient, was named LURET (lung cancer with RET rearrangement study) trial. Because vandetanib was approved by the US Food and Drug Administration (FDA) for the treatment of advanced medullary thyroid cancer that was frequently activated by RET mutations, therapeutic effect against RET fusions is also expected in LADC. In fact, a RET-fusion positive LADC responded to vandetanib in the USA 42) .
The nationwide cancer genome screening project by NGS-based was renewed and started as SCRUM-Japan from March 2015. The purpose of this consortium is to find rare targetable genetic aberrations in lung cancer by using a multiplex genetic diagnosis panel (Oncomine® Cancer Research Panel), which investigate aberrations in >100 genes 43) . Genomic screenings of SQLC and SCLC have also started.
Conclusion
Personalized therapy against driver gene aberrations has been significantly developed for LADC, but not for other types of lung cancer. The need of this therapy will be increasing in all cancer subtypes. A genome screening project has just been started to find patients with driver gene aberrations, and is expected to lead to effective cancer therapy.
